CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Sale | −7,243 | $246.57 | $1.8M | 10,980 |
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Sale | −6,480 | $247.63 | $1.6M | 4,500 |
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Sale | −3,900 | $248.63 | $970K | 600 |
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Sale | −600 | $249.25 | $150K | 0 |
| 2025-03-03 | OYLER JOHN Chief Executive Officer | Option exercise · Share Option (Right to Buy) | −2,533,531 | 7,566,969 | ||
| 2025-02-28 | Wu Xiaobin President, COO & GM China | Sale | −0 | 0 | ||
| 2025-02-28 | BAKER BROS. ADVISORS LP Director | Sale | −60,851 | $260.00 | $15.8M | 730,642 |
| 2025-02-28 | BAKER BROS. ADVISORS LP Director | Sale | −671,976 | $260.00 | $174.7M | 8,068,411 |
| 2025-02-27 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −1,205 | $275.00 | $331K | 0 |
| 2025-02-21 | Wang Lai Global Head of R&D | Sale 10b5-1 | −1,327 | $254.82 | $338K | 3,673 |
| 2025-02-21 | Wang Lai Global Head of R&D | Sale 10b5-1 | −575 | $255.86 | $147K | 3,098 |
| 2025-02-21 | Wang Lai Global Head of R&D | Sale 10b5-1 | −479 | $256.70 | $123K | 2,619 |
| 2025-02-21 | Wang Lai Global Head of R&D | Sale 10b5-1 | −437 | $258.18 | $113K | 2,182 |
| 2025-02-21 | Wang Lai Global Head of R&D | Sale 10b5-1 | −1,782 | $258.73 | $461K | 400 |
| 2025-02-21 | Wang Lai Global Head of R&D | Sale 10b5-1 | −400 | $260.17 | $104K | 0 |
| 2025-02-21 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −504 | $256.84 | $129K | 698 |
| 2025-02-21 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −598 | $258.69 | $155K | 100 |
| 2025-02-21 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −100 | $260.22 | $26K | 0 |
| 2025-02-20 | Wu Xiaobin President, COO & GM China | Option exercise 10b5-1 | +21,267 | $169.65 | $3.6M | 21,267 |
| 2025-02-20 | Wu Xiaobin President, COO & GM China | Sale 10b5-1 | −21,267 | $240.07 | $5.1M | 0 |
Page 32 of 71 · 1,406 trades